Overview of Retatrutide Retatrutide (LY3437943) is a novel, single-molecule synthetic peptide currently being extensively researched for its unique tri-agonist activity. It is engineered to bind to and activate three distinct metabolic receptors simultaneously: the Glucose-Dependent Insulinotropic Polypeptide (GIP) receptor, the Glucagon-Like Peptide-1 (GLP-1) receptor, and the Glucagon receptor (GCGR).
By modifying the peptide backbone with a C20 fatty diacid moiety, the compound demonstrates delayed clearance and extended stability in testing environments. In laboratory models, Retatrutide is utilized to study the synergistic effects of activating all three hormone receptors, providing researchers with a unique tool to evaluate multi-pathway interactions related to energy expenditure, lipid metabolism, and glycemic regulation.
Research Applications:
-
Metabolic Pathway Analysis: Investigating the synergistic biochemical responses when GLP-1, GIP, and GCGR are activated simultaneously in cellular models.
-
Receptor Pharmacology & Binding Assays: Observing competitive binding affinities, intracellular cAMP accumulation, and receptor downregulation.
-
Energy Expenditure Studies: Utilizing isolated tissue assays to study mechanisms of adipocyte lipolysis and insulin secretion pathways.
The Secra Labs Quality Guarantee This product has been synthesized to the highest clinical standards. Every batch of Secra Labs Retatrutide undergoes rigorous independent HPLC and MS testing to ensure a minimum purity threshold of 99%, guaranteeing highly stable, reproducible results for your complex metabolic assays.
Disclaimer: This product is sold strictly for in-vitro laboratory research, development, and analytical purposes. It is not a drug, cosmetic, or food additive. It has not been evaluated by the FDA and is strictly prohibited from human or animal consumption, injection, or dosing.
Reviews
There are no reviews yet.